EBR Systems (EBRCZ) plans CCO transition amid push to speed field training

Q: What leadership change did EBR Systems (EBRCZ) announce in this 8-K?

EBR Systems announced the impending departure of Chief Commercial Officer Erik Strandberg, who will leave in the coming months. CEO John McCutcheon will assume responsibility for the commercial organization while the company conducts a search for a new Chief Commercial Officer.

Q: Did EBR Systems (EBRCZ) indicate any disagreement behind the CCO’s departure?

No. EBR Systems stated that Mr. Strandberg’s departure is not the result of any dispute or disagreement with the company on matters related to its operations, policies or practices.

Q: Does EBR Systems (EBRCZ) expect the CCO change to affect U.S. commercial adoption?

EBR Systems stated that it does not expect any negative impact on U.S. commercial adoption resulting from the Chief Commercial Officer transition.

Q: Will EBR Systems (EBRCZ) disclose the terms of any separation agreement with the CCO?

Yes. EBR Systems expects to enter into an agreement with Mr. Strandberg relating to his departure and plans to disclose the material terms of any such agreement in a later amendment.

Q: What operational focus did EBR Systems (EBRCZ) highlight during the CCO transition?

EBR Systems said it will focus on accelerating outstanding training requirements in its field team to ensure capacity to support ongoing and increasing clinical demand for its WiSE wireless cardiac pacing technology.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

EBR Systems, Inc. (EBRCZ) reported a leadership transition in its commercial organization. The company announced the impending departure of Chief Commercial Officer Erik Strandberg, who will leave in the coming months, with his final date still to be determined. EBR states that his departure is not due to any dispute or disagreement regarding operations, policies or practices. President and Chief Executive Officer John McCutcheon will assume responsibility for the commercial organization while a search is conducted for a successor Chief Commercial Officer. EBR indicated it expects to enter into a separation agreement with Mr. Strandberg and plans to disclose its material terms in a future amendment. In an accompanying press release, the company stated it does not expect any negative impact on U.S. commercial adoption from this change and plans to focus on accelerating training requirements in the field team to support ongoing and increasing clinical demand for its WiSE wireless cardiac pacing technology.

Positive

None.

Negative

Chief Commercial Officer departure: EBR Systems announced that Chief Commercial Officer Erik Strandberg will leave the company in the coming months, creating leadership turnover in the commercial organization, even though the company states it does not expect a negative impact on U.S. commercial adoption.

8-K Event Classification

3 items: 5.02, 8.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Press release date: August 21, 2026 Form 8-K signature date: August 24, 2026 Press release exhibit number: 99.1

3 metrics

Press release date August 21, 2026 Date EBR Systems announced the impending departure of its Chief Commercial Officer

Form 8-K signature date August 24, 2026 Date the report was signed on behalf of EBR Systems by the Chief Executive Officer

Press release exhibit number 99.1 Exhibit number for the press release announcing the CCO transition

Key Terms

Chief Commercial Officer, Cardiac Resynchronisation Therapy, CHESS Depositary Interests, Regulation S, +1 more

5 terms

Chief Commercial Officer financial

"announced the impending departure of Erik Strandberg, Chief Commercial Officer"

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

Cardiac Resynchronisation Therapy medical

"patients requiring Cardiac Resynchronisation Therapy (CRT)"

CHESS Depositary Interests financial

"ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs)"

CHESS depositary interests are tradable certificates used on the Australian settlement system that represent ownership of underlying foreign shares held by a custodian. They let investors buy and sell foreign-listed stocks on the local exchange as if they were domestic shares, simplifying trading, dividend collection and record-keeping, though they may involve custodian fees and can alter certain direct shareholder rights and tax treatments.

Regulation S regulatory

"issued in reliance on the exemption from registration contained in Regulation S"

Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.

forward-looking statements regulatory

"This announcement contains or may contain forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What leadership change did EBR Systems (EBRCZ) announce in this 8-K?

EBR Systems announced the impending departure of Chief Commercial Officer Erik Strandberg, who will leave in the coming months. CEO John McCutcheon will assume responsibility for the commercial organization while the company conducts a search for a new Chief Commercial Officer.

Did EBR Systems (EBRCZ) indicate any disagreement behind the CCO’s departure?

No. EBR Systems stated that Mr. Strandberg’s departure is not the result of any dispute or disagreement with the company on matters related to its operations, policies or practices.

Who will oversee commercial operations at EBR Systems (EBRCZ) after the CCO leaves?

President and CEO John McCutcheon will assume responsibility for EBR Systems’ commercial organization during Mr. Strandberg’s transition and while the company searches for a replacement Chief Commercial Officer.

Does EBR Systems (EBRCZ) expect the CCO change to affect U.S. commercial adoption?

EBR Systems stated that it does not expect any negative impact on U.S. commercial adoption resulting from the Chief Commercial Officer transition.

Will EBR Systems (EBRCZ) disclose the terms of any separation agreement with the CCO?

Yes. EBR Systems expects to enter into an agreement with Mr. Strandberg relating to his departure and plans to disclose the material terms of any such agreement in a later amendment.

What operational focus did EBR Systems (EBRCZ) highlight during the CCO transition?

EBR Systems said it will focus on accelerating outstanding training requirements in its field team to ensure capacity to support ongoing and increasing clinical demand for its WiSE wireless cardiac pacing technology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/24/2026 - 02:08 PM Accepted by SEC EDGAR 08/24/2026 - 02:08 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 20, 2026

EBR SYSTEMS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		000-56671		57-1164669
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

480 Oakmead Parkway

Sunnyvale, CA 94085

(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (408) 720-1906

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None.	None.	None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Transition of Chief Commercial Officer

On August 21, 2026, EBR Systems, Inc. (the “Company”) announced the impending departure of Erik Strandberg, Chief Commercial Officer, who will be leaving the Company in the coming months, which final date has yet to be determined. Mr. Strandberg’s departure is not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

John McCutcheon, the Company’s President and Chief Executive Officer, will assume responsibility for the Company’s commercial organization while the Company conducts a search to identify a successor Chief Commercial Officer.

The Company expects to enter into an agreement with Mr. Strandberg at a later date relating to his departure and will disclose the material terms of any such agreement by an amendment to this Current Report on Form 8-K.

Item 8.01. Other Events.

On August 21, 2026, the Company issued a press release announcing the departure of Mr. Strandberg as the Company’s Chief Commercial Officer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 8.01, including the related information set forth in the press release attached hereto as Exhibit 99.1, is being “furnished” and shall not be deemed “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of EBR Systems, Inc. issued on August 20, 2026 (furnished herewith)

104		Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 24, 2026	EBR SYSTEMS, INC.

	By:	/s/ John McCutcheon
	Name:	John McCutcheon
	Title:	Chief Executive Officer

Exhibit 99.1

ASX ANNOUNCEMENT

21 August 2026

EBR announces transition of Chief Commercial Officer

Santa Clara, California; 21 August 2026: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, today announced the impending departure of Erik Strandberg, Chief Commercial Officer, who will be leaving the Company in the coming months. During Mr. Strandberg’s transition out, President and CEO John McCutcheon will assume responsibility for the commercial organization as a search is conducted to identify a replacement Chief Commercial Officer. The Company does not expect any negative impact on US commercial adoption because of this change. During this period the Company will focus on accelerating outstanding training requirements in the field team to ensure there is capacity to support ongoing and increasing clinical demand for WiSE.

John McCutcheon, EBR Systems’ President & Chief Executive Officer said:

“We thank Erik for his significant contributions to EBR, particularly his efforts to build a best-in-class commercial organization in preparation for the launch of the WiSE^® System. We will continue to build the capabilities of our exceptional commercial team as we execute our strategy of selective expansion of hospitals and increased utilisation of WiSE within existing accounts. Our field sales and clinical organization will continue to provide nothing but the most exemplary patient care and physician training.”

ENDS

This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a Committee of the Board of Directors.

For more information, please contact:

Company	Investor Relations
Andrew Shute	Gabriella Hold
Chief Corporate Development Officer	The Capital Network
P: +44 7730 691421	P: +61 2 7257 7338
E: investors@ebrwise.com	E: gaby@thecapitalnetwork.com.au

	Julia Maguire
	The Capital Network
	P: +61 2 7257 7338
	E: julia@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR SYSTEMS, INC. (ARBN 654 147 127)

4600 Patrick Henry Drive, Santa Clara CA 95054 USA T: +1 408 720 1906 W: https://ebrsystemsinc.com/

EBR Systems’ WiSE Technology

EBR Systems’ WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart’s left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company’s control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems’ current expectations and inherently involve significant risks and uncertainties. EBR Systems’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC’s website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR’s ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR’s CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.